Highview Capital Management LLC DE Reduces Holdings in Johnson & Johnson (NYSE:JNJ)

Highview Capital Management LLC DE reduced its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 4.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,212 shares of the company’s stock after selling 500 shares during the period. Johnson & Johnson comprises approximately 1.4% of Highview Capital Management LLC DE’s holdings, making the stock its 18th biggest position. Highview Capital Management LLC DE’s holdings in Johnson & Johnson were worth $1,832,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also modified their holdings of JNJ. Morton Brown Family Wealth LLC raised its position in shares of Johnson & Johnson by 78.0% during the 2nd quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock worth $32,000 after buying an additional 78 shares in the last quarter. Goodman Advisory Group LLC purchased a new position in Johnson & Johnson during the second quarter valued at approximately $39,000. Cardinal Capital Management Inc. grew its position in Johnson & Johnson by 333.3% in the second quarter. Cardinal Capital Management Inc. now owns 260 shares of the company’s stock worth $46,000 after acquiring an additional 200 shares in the last quarter. First Bank & Trust grew its position in Johnson & Johnson by 69.6% in the second quarter. First Bank & Trust now owns 380 shares of the company’s stock worth $67,000 after acquiring an additional 156 shares in the last quarter. Finally, Heritage Wealth Management LLC acquired a new stake in shares of Johnson & Johnson in the second quarter worth $84,000. 67.94% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on JNJ shares. Atlantic Securities dropped their price objective on shares of Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a research note on Wednesday, October 19th. Raymond James cut their target price on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 19th. StockNews.com began coverage on shares of Johnson & Johnson in a report on Wednesday, October 12th. They set a “strong-buy” rating on the stock. Bank of America decreased their price target on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a research note on Friday, October 14th. Finally, Credit Suisse Group began coverage on shares of Johnson & Johnson in a research note on Thursday, November 17th. They issued a “neutral” rating and a $170.00 target price for the company. Seven investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average target price of $181.75.

Johnson & Johnson Stock Down 0.3 %

JNJ stock opened at $168.31 on Tuesday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43. The company has a market capitalization of $440.04 billion, a price-to-earnings ratio of 23.44, a PEG ratio of 3.21 and a beta of 0.56. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The stock has a fifty day moving average of $176.07 and a 200-day moving average of $171.13.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be issued a $1.13 dividend. The ex-dividend date is Friday, February 17th. This represents a $4.52 annualized dividend and a dividend yield of 2.69%. Johnson & Johnson’s payout ratio is currently 62.95%.

Insider Buying and Selling at Johnson & Johnson

In related news, VP Thibaut Mongon sold 35,246 shares of the firm’s stock in a transaction dated Friday, November 4th. The stock was sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the transaction, the vice president now directly owns 40,133 shares of the company’s stock, valued at approximately $6,869,966.94. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CFO Joseph J. Wolk sold 14,781 shares of the business’s stock in a transaction on Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total value of $2,654,667.60. Following the completion of the transaction, the chief financial officer now owns 35,812 shares in the company, valued at $6,431,835.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Thibaut Mongon sold 35,246 shares of Johnson & Johnson stock in a transaction on Friday, November 4th. The stock was sold at an average price of $171.18, for a total value of $6,033,410.28. Following the completion of the sale, the vice president now directly owns 40,133 shares of the company’s stock, valued at approximately $6,869,966.94. The disclosure for this sale can be found here. Insiders have sold a total of 233,611 shares of company stock valued at $40,960,735 in the last 90 days. Corporate insiders own 0.35% of the company’s stock.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.